Major pharma disruption--about time?

Eli Lilly (Zepbound) and Novo Norodisk (Wegovy) both go direct to consumers with weight loss drugs—a shot over the bow at pharmacy benefit managers and our bizarre drug costs.

What do you think? What frustrates you about all this? What’s your experience with PBMs, health insurers, and prescription drug access and pricing? For you, your spouse, your partner, your aging parents, or your kids? Comment, start a Chat, or respond to the Note; we’re really very interested in your thoughts on this—because it impacts a whole lot of pe…